கில்லர்மோ கார்சியா மானேரோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கில்லர்மோ கார்சியா மானேரோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கில்லர்மோ கார்சியா மானேரோ Today - Breaking & Trending Today

Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2021 Virtual Congress


Share this article
Share this article
LEXINGTON, Mass., May 12, 2021 /PRNewswire/  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021. The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).
We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful, said James Dentz ....

United States , James Dentzer , Guillermo Garcia Manero , University Of Texas Md Anderson Cancer Center , Drug Administration , European Hematology Association , Md Anderson Cancer Center , Curis Inc , Exchange Commission , Department Of Leukemia , Roche Group , Virtual Congress , Biology Translational Research , Chief Executive Officer , Dose Escalation Trial , Novel Oral , Acute Myelogenous Leukemia , Myelodysplastic Syndrome , Interim Report , Antitumor Effects , Human Acute Myeloid Leukemia , Translational Research , Myelodysplastic Syndromes , Orphan Drug Designation , Looking Statements , Securities Litigation Reform Act ,

Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders


Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 demonstrate Opdivo plus Yervoy and Opdivo plus chemotherapy’s potential to address unmet needs in …
First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma ....

United States , Jakarta Raya , United Kingdom , South Korea , Katelyn Cutts , Antonio Piga , Lucjan Wyrwicz , Christopher Pocock , Ronanj Kelly , Markush Moehler , James Larkin , Evanj Lipson , Ulrich Germing , Michael Amatangelo , Gailj Roboz , Dennis Revicki , Martin Reck , Ali Taher , Robertj Motzer , Daratumumab Dara , Husseina Tawbi , Hemophagocytic Lymphohistiocytosis , Sara Lonardi , Luisg Paz , Carfilzomib Cfz , Albert Oriol ,